Navigation Links
Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting

Houston, TX
  • Diffuse Large B-Cell Lymphoma Poster Presentation
  • Title: The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL (#2716)
  • Session: Lymphoma – Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
  • Date/Time: Sunday, December 11, 2011; 6:00 p.m. – 8:00 p.m. Pacific Time
  • Location: Hall GH
  • Presenter: Joseph Buggy, PhD, Pharmacyclics, Inc., Sunnyvale, CA

  • Non-Clinical Presentations

  • Multiple Myeloma and Waldenstrom Oral Presentation
  • Title: Targeting Bruton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenstrom Macroglobulinemia via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine secretion, and Myeloma Stem-like Cells in the Bone Marrow Microenvironment (#883)
  • Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Targeting the Microenvironment
  • Date/Time: Monday, December 12, 2011; 6:15 p.m. Pacific Time
  • Location: Room 6A
  • Presenter: Yu-Tzu Tai, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Chronic Lymphocytic Leukemia Oral Presentation
  • Title: The Bruton Tyrosine Kinase Inhibitor, PCI-32765, Inhibits Activation and Proliferation of Human Chronic Lymphocytic Leukemia Cells in the NSG Xenograph Mouse Model of the Tissue Microenvironment (#596)
  • Session: Pre-Clinical – Chemotherapy and Biologic Agents: Novel targeted therapy of B-cell malignancies
  • Date/Time: Monday, December 12, 2011; 3:00 p.m. Pacific Time
  • Location: Room 31
  • Presenter: Sarah E. M. Herman, PhD, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland

  • Chronic Lymphocytic Leukemia Oral Prese

  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
    2. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
    3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
    4. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
    5. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
    6. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
    7. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
    8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    9. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
    10. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
    11. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
    Post Your Comments:
    (Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
    (Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
    (Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
    Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
    ... The U.S. Food and Drug Administration,s (FDA) ... decided today that it could not recommend approval ... the currently available data (13-3); but, voted unanimously ... a reader training program that demonstrates reader accuracy ...
    ... Medical Simulation Corporation (MSC) will highlight a ... providers at the 2011 International Meeting on Simulation ... MSC,s full-service simulation training and education services are ... all healthcare providers. MSC,s complete line of equipment ...
    Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare 2
    (Date:9/22/2014)... On Tuesday, September 16th, 2014, at 8:00 p.m. ... “KC After Dark.” Hosted by top WRNW1 host, ... every Tuesday at 8:00 p.m. EST. WRNW1 had a promotion ... and because of the amazing turnout for their first show, ... 500 callers. , During this comical, yet professional show, ...
    (Date:9/22/2014)... September 22, 2014 The Philadelphia 100, ... Greater Philadelphia region each year, is considered a hallmark ... manufacturer MK Precision is proud to announce it has ... MK Precision will attend the Philadelphia 100 ... the premiere business events of the year, as well ...
    (Date:9/22/2014)... 2014 (HealthDay News) -- All sexually active women ... common sexually transmitted infections: chlamydia and gonorrhea, according ... Task Force. The task force noted ... 24 years of age and pregnant women. ... noticeable symptoms. As a result, many infections go ...
    (Date:9/22/2014)... Amy Norton HealthDay Reporter ... may fare better when newborn intensive care units (NICU) set ... infants, a new study finds. Researchers at one children,s ... and were less distressed when their NICU switched from the ... findings, published online Sept. 22 in the journal Pediatrics ...
    (Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
    Breaking Medicine News(10 mins):Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Looking ahead: Whole eye transplant under development 2
    ... The Autism Research Institute states that many of those ... appropriately diagnosed and treated may result in marked improvementATLANTA, ... every 20 seconds in the US. Autism is ... AIDS combined. The Federal Centers for Disease Control ...
    ... SANTA MONICA, Calif., April 6 Cord Blood America, Inc. ... preservation company ( ) ... to families nationwide and internationally, is pleased to announce that ... long term debt by approximately $750,000, or 12 percent. ...
    ... place in line at local emergency departments and ... has selected Trevelino/Keller Communications Group, Inc., one of ... launch the company nationally and build out its ... Alabama and Florida -- as it pursues national ...
    ... a systemic disease or an autoimmune disorder in which the ... of cells called the synovium that lines and lubricates the ... and crippling stiffness, particularly of the hands and feet. It ... mobility and quality of life. RA cannot be confirmed or ...
    ... solutions provider, is pleased to announce that its entire suite of ... , ... Charlotte, NC (PRWEB) April 6, 2009 -- IQMax, ... that its entire suite of healthcare solutions is available on Blackberry® ...
    ... high blood pressure and heart disease during a clinical trial for osteoarthritis. ... ... Company, a Bendigo based company who manufactures a topical pain relief lotion ... trial for their flagship product, Elmore Oil., , ,The trial was headed ...
    Cached Medicine News:Health News:Alarming Rise in Autism Brings Hundreds of Parents, Researchers and Clinicians Together from Around the World to Atlanta April 17-19, 2009 2Health News:Cord Blood Announces $1.75 Million Reduction in Long Term Debt 2Health News:Imagine No More Waits for Emergency Room Care ... InQuickER Chooses Trevelino/Keller Communications to Launch First Service of Its Kind 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 3Health News:IQMax Delivers Healthcare Solutions to Blackberry Devices 2Health News:Arthritis Trial Leads to Potential Cure for High Blood Pressure 2
    The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
    Minimal M9CA Broth...
    Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
    Medicine Products: